23/06/2026 Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia Sanofi’s tolebrutinib approved in the EU for secondary progressive multiple sclerosis without relapses Abbive announced EC approval of risankizumab for the treatment of pediatric patients with oderate to severe plaque psoriasis Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia (Ref) Sanofi announced that the Ministry of Health, Labour and Welfare in Japan had granted marketing and

11/06/2026 Nipocalimab demonstrated a durable hemoglobin response and rapid onset of effect in a Phase 2/3 study in wAIHA Climb Bio announced initial Phase 1b data for budoprutug in ITP at EHA Congress 2026 Takeda’s Zasocitinib significantly outperformed deucravacitinib in a head-to-head Phase 3 Psoriasis Study Nipocalimab demonstrated a durable hemoglobin response and rapid onset of effect in a Phase 2/3 study in wAIHA (Ref) Johnson & Johnson presented results from the Phase